Clinical Trial Update: Sunitinib in Treating Patients With Recurrent Malignant Gliomas [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sunitinib for adults with recurrent malignant gliomas has completed; results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Diffuse Astrocytoma
• Giant Cell Glioblastoma
• Glioblastoma
• Gliosarcoma
• Oligoastrocytoma
• Oligodendroglioma
• Pineal Region Glioma

Drugs mentioned

• Sunitinib (sunitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Anaplastic Astrocytoma, Adult Diffuse Astrocytoma | Phase 2 | Status: COMPLETED | Results posted: 2016-02-29